| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
8-Hydroxycoumarin targets various biological pathways. It can act as a superoxide anion scavenger and inhibits lipid peroxidation. It has been shown to activate Jak2 V617F. Coumarin derivatives are known to interact with G protein-coupled receptors (GPCRs), with some exhibiting potent GPCR activation or inhibition.
|
|---|---|
| ln Vitro |
In vitro, 8-hydroxycoumarin demonstrates lipid peroxidation inhibitory activity with an IC50 of 58.13 mM. Derivatives synthesized from 8-hydroxycoumarin have shown antiproliferative activity against human hepatocellular carcinoma (HepG2) cells. It also exhibits potent superoxide anion scavenging activity.
|
| ln Vivo |
In vivo, 8-hydroxycoumarin has been shown to be an effective adjuvant for the treatment of cervical cancer and has anti-tumor activity against squamous carcinoma cells. Its derivatives have demonstrated anticancer activity, suggesting potential for therapeutic applications.
|
| Enzyme Assay |
Non-cellular assays for 8-hydroxycoumarin typically involve measuring its antioxidant activity using DPPH or ABTS radical scavenging assays. Lipid peroxidation inhibitory activity can be assessed using standard in vitro lipid peroxidation models with IC50 determination.
|
| Cell Assay |
Cellular assays for 8-hydroxycoumarin are conducted using cancer cell lines such as HepG2 (hepatocellular carcinoma) to assess its antiproliferative activity. DNA flow cytometry assays may be used to reveal cell cycle arrest and activation of apoptosis.
|
| Animal Protocol |
In vivo animal experiments for 8-hydroxycoumarin are limited, as it is primarily a research compound. Studies may involve xenograft models to assess its anti-tumor activity as a single agent or in combination with other therapies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 8-hydroxycoumarin are not well-characterized. Its molecular weight is 146.14 g/mol. As a small, lipophilic molecule, it is likely absorbed and metabolized. Specific ADME data are not readily available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for 8-hydroxycoumarin are limited. It is generally considered a research chemical. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin and eye irritation.
|
| References | |
| Additional Infomation |
Reports have indicated that Murraya paniculata and Murraya exotica contain 8-hydroxycoumarin, and relevant data are available for reference.
8-Hydroxycoumarin is a key intermediate in the synthesis of coumarin derivatives with potential pharmacological applications. It is used in research on cancer, oxidative stress, and GPCR biology. It is a valuable building block for medicinal chemistry. |
| Molecular Formula |
C9H6O3
|
|---|---|
| Molecular Weight |
162.14
|
| Exact Mass |
162.032
|
| CAS # |
2442-31-1
|
| PubChem CID |
122783
|
| Appearance |
Off-white to pink solid powder
|
| Density |
1.403g/cm3
|
| Boiling Point |
361.6ºC at 760mmHg
|
| Flash Point |
170.3ºC
|
| Vapour Pressure |
9.86E-06mmHg at 25°C
|
| Index of Refraction |
1.64
|
| LogP |
1.498
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C(=C1)O)OC(=O)C=C2
|
| InChi Key |
DPTUTXWBBUARQB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6O3/c10-7-3-1-2-6-4-5-8(11)12-9(6)7/h1-5,10H
|
| Chemical Name |
8-hydroxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (308.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1675 mL | 30.8375 mL | 61.6751 mL | |
| 5 mM | 1.2335 mL | 6.1675 mL | 12.3350 mL | |
| 10 mM | 0.6168 mL | 3.0838 mL | 6.1675 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
